A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia; Schizophrenia and disorders with psychotic features
- Focus Proof of concept; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 15 Sep 2015 Top line results published in the Media Release.
- 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.